Clinical trial

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

NCT02087176

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention AZD1775 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention AZD1775 Placebo Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Antimitotic Agent Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention pegfiligrastim Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2014-03-01

PhasePHASE2

Conditions

Previously Treated Non Small Cell Lung Cancerunresolved

Interventions

AZD1775DRUG

AZD1775 PlaceboDRUG

Antimitotic AgentDRUG

pegfiligrastimDRUG

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

NashvilleTennessee, United States1 PittsburghPennsylvania, United States1 BirminghamAlabama, United States1 CincinnatiOhio, United States1 DurhamNorth Carolina, United States1 OrlandoFlorida, United States1 MilwaukeeWisconsin, United States1 LouisvilleKentucky, United States1 ScottsdaleArizona, United States1 WichitaKansas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02087176 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.